Cramer dubs Regeneron stock a ‘favourite’ after two new FDA approvals

August 21, 2023 09:45 AM PDT | By Invezz

Cramer dubs Regeneron stock a ‘favourite’ after two new FDA approvals — Image source: Invezz

Jim Cramer is bullish on Regeneron stock

Shares of the biotech giant responded with an over 3.0% gain this morning.

Regeneron stock is now worth $145 more versus early July. Still, famed investor Jim Cramer is convinced that it has more room to the upside. On CNBC’s “Squawk on the Street”, he said today:

This is a remarkable drug for macular degeneration. One of my favourite stocks is Regeneron. I think it’s going to be worth more.

Note that Eylea HD is just as safe and effective for patients of age-related macular degeneration but with fewer injections. On Monday, the Food and Drug Administration approved Regeneron’s Veopoz for Chaple disease as well.

Oppenheimer raises its price target on REGN

Jim Cramer is particularly bullish on the management of CEO Leonard Schleifer – who cofounded the Nasdaq-listed firm in 1988.

Who shares his optimism on Regeneron stock is Hartaj Singh – an Oppenheimer analyst. Singh raised his price target on shares of this Tarrytown-headquartered firm today to $1,050 and said:

While there have been concerns about competition to Eylea 2mg over the last year, we expect Eylea HD to give Regeneron Pharmaceuticals’ eye franchise its mojo back.

His price objective suggests another 25% upside from here. The stock market news arrives a couple weeks after Regeneron Pharmaceuticals reported its financial results for the second quarter that handily topped Street estimates.

The post Cramer dubs Regeneron stock a ‘favourite’ after two new FDA approvals appeared first on Invezz.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.